Aniracetam (Ro 13-5057) for the Treatment of Senile Dementia of Alzheimer Type: Results of a Multicentre Clinical Study

Authors:
  • LPLucilla Parnetti
    Lucilla Parnetti
  • LBLuisa Bartorelli
    Luisa Bartorelli
  • SBSalvatore Bonaiuto
    Salvatore Bonaiuto
  • DCDomenico Cucinotta
    Domenico Cucinotta
  • MCMarco Cuzzupoli
    Marco Cuzzupoli
  • FEFranco Erminio
    Franco Erminio
  • MMMaurizio Maggioni
    Maurizio Maggioni
  • GMGiorgio Marini
    Giorgio Marini
  • EPEnrico Paciaroni
    Enrico Paciaroni
  • FPFausto Pedrazzi
    Fausto Pedrazzi
  • MPMarino Peruzza
    Marino Peruzza
  • USUmberto Senin
    Umberto Senin
Publisher website
Google Scholar
Abstract
One hundred and fifteen patients suffering from mild to moderate cognitive impairment fulfilling NINCDS-ADRDA criteria for probable dementia of Alzheimer type were treated for 6 months with a new nootropic drug, aniracetam (Ro 13–5057) in a double-blind randomized study versus piracetam. The two treatment groups were comparable at baseline for demographic and behavioural parameters and symptomatology. All patients underwent clinical, behavioural and psychometric evaluation every other month. The aniracetam group showed statistically significant improvements over the majority of psychobehavioural parameters used to assess efficacy. To a lesser extent the piracetam group also showed an improvement. Excellent drug tolerability was found in both groups.